SAN

76.94

+0.68%↑

UCB

257

+1.3%↑

SHL.DE

38.53

+0.76%↑

ARGX

615.2

-0.13%↓

PHIA

24.55

+0.66%↑

SAN

76.94

+0.68%↑

UCB

257

+1.3%↑

SHL.DE

38.53

+0.76%↑

ARGX

615.2

-0.13%↓

PHIA

24.55

+0.66%↑

SAN

76.94

+0.68%↑

UCB

257

+1.3%↑

SHL.DE

38.53

+0.76%↑

ARGX

615.2

-0.13%↓

PHIA

24.55

+0.66%↑

SAN

76.94

+0.68%↑

UCB

257

+1.3%↑

SHL.DE

38.53

+0.76%↑

ARGX

615.2

-0.13%↓

PHIA

24.55

+0.66%↑

SAN

76.94

+0.68%↑

UCB

257

+1.3%↑

SHL.DE

38.53

+0.76%↑

ARGX

615.2

-0.13%↓

PHIA

24.55

+0.66%↑

Inicio・Lista de Acciones・Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi SA

Cerrado

SectorSalud

80.15 0.19

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

79.2

Máximo

80.8

Métricas clave
By Trading Economics
Ingresos	-33M 43M
Ventas	7.9M 218M
P/B Media del Sector	34.025 61.417
BPA	0.834
Margen de beneficio	19.539
Empleados	1,950
EBITDA	-21M 63M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 meses	+8.64% upside

Dividendos
By Dow Jones
Próximas Ganancias	7 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	130M 4.1B
Apertura anterior	79.96
Cierre anterior	80.15

Noticias sobre sentimiento de mercado

By Acuity

13%

87%

14 / 351 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

51.1 / N/A Soporte y Resistencia

Laboratorios Farmaceuticos Rovi SA Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

16 mar 2026, 21:37 UTC

Adquisiciones, fusiones, absorciones

Lensar and Alcon Agree to Terminate Merger

16 mar 2026, 19:06 UTC

Noticias de Eventos Importantes

Mideast Loses 12 Million Boe/d Following Hormuz Closure: Rystad -- OPIS

16 mar 2026, 17:44 UTC

Adquisiciones, fusiones, absorciones

Novartis Issues Debt Offering to Help Fund $12 Billion Acquisition of Avidity Biosciences

16 mar 2026, 23:46 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

16 mar 2026, 23:46 UTC

Charlas de Mercado

Nikkei May Rise After Oil Prices Decline -- Market Talk

16 mar 2026, 23:37 UTC

Charlas de Mercado

Gold Edges Higher on Possible Technical Recovery -- Market Talk

16 mar 2026, 23:05 UTC

Charlas de Mercado

Slumping Consumer Confidence Highlights Risk Around RBA Hike -- Market Talk

16 mar 2026, 21:56 UTC

Charlas de Mercado

DUG Technology's Stock Fall Creates Opportunity -- Market Talk

16 mar 2026, 21:41 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Global Equities Roundup: Market Talk

16 mar 2026, 21:41 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Clouds Gather Over Auckland Intl Airport as Airlines Up Fares -- Market Talk

16 mar 2026, 20:59 UTC

Adquisiciones, fusiones, absorciones

Alcon: Transaction Unattractive to Pursue Further in Light of FTC's Opposition

16 mar 2026, 20:59 UTC

Adquisiciones, fusiones, absorciones

Alcon: Delay and Associated Costs of Extended Regulatory Review Has Rendered Deal Unattractive to Pursue Further

16 mar 2026, 20:59 UTC

Adquisiciones, fusiones, absorciones

Alcon Entered Agreement With LENSAR to Terminate Merger Agreement

16 mar 2026, 20:57 UTC

Adquisiciones, fusiones, absorciones

Alcon and LENSAR, Inc. Agree to Terminate Merger Agreement

16 mar 2026, 20:51 UTC

Adquisiciones, fusiones, absorciones

Nvidia-Backed Nscale Plans Huge Data Center Cluster in West Virginia -- WSJ

16 mar 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

16 mar 2026, 20:50 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Energy & Utilities Roundup: Market Talk

16 mar 2026, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

16 mar 2026, 20:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

16 mar 2026, 19:53 UTC

Noticias de Eventos Importantes

U.S. Allies Rebuff Trump's Demand for Help Opening Strait of Hormuz -- WSJ

16 mar 2026, 19:43 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

16 mar 2026, 19:43 UTC

Charlas de Mercado

Nvidia Sees $1 Trillion in Blackwell, Rubin Orders Through 2027 -- Market Talk

16 mar 2026, 19:37 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Natural Gas Follows Oil Prices Lower -- Market Talk

16 mar 2026, 19:20 UTC

Noticias de Eventos Importantes

Stock Market Today: Dow Jumps, Brent Crude Pulls Back From $105 -- WSJ

16 mar 2026, 19:17 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Crude Oil Sinks on Signals from Strait of Hormuz -- Market Talk

16 mar 2026, 19:00 UTC

Charlas de Mercado

Bank of Canada Needs Dovish Approach Based on Weak Data -- Market Talk

16 mar 2026, 18:23 UTC

Charlas de Mercado

LME Restarts Trading After Outage -- Market Talk

16 mar 2026, 17:36 UTC

Noticias de Eventos Importantes

Oil Prices Fall as Trump Says Hormuz Help Is Coming. Tankers Getting Through, Bessent Adds. -- Barrons.com

16 mar 2026, 17:19 UTC

Charlas de Mercado

Grains Sink as Investors Steer Toward Equities -- Market Talk

16 mar 2026, 17:14 UTC

Noticias de Eventos Importantes

Trump Ends News Conference

Comparación entre iguales

Cambio de precio

Laboratorios Farmaceuticos Rovi SA Esperado

Precio Objetivo

By TipRanks

8.64% repunte

Estimación a 12 meses

Media 86.75 EUR 8.64%

Máximo 90 EUR

Mínimo 83.5 EUR

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Laboratorios Farmaceuticos Rovi SA Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

2 ratings

Comprar

Mantener

Vender

De acuerdo con 2 analistas que ofrecen calificaciones bursátiles a para Laboratorios Farmaceuticos Rovi SA Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

51.1 / N/ASoporte y Resistencia

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

Sentimiento

By Acuity

14 / 351 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.